A Prospective, Multicentre, Randomised, Assessor Blinded Study Comparing the Efficacy, Including Patient Reported Outcomes of Two Different Daily gekoTM Treatment Durations in Conjunction With Standard Care, With Each Other and to Standard Care Alone, in Patients With Venous Leg Ulcers

Firstkind Ltd23 sites in 1 country171 target enrollmentApril 24, 2018

Overview

Brief Summary

Eight weeks, comprised of four weeks Run-in Phase of Standard Care (SC) treatment followed by four weeks of treatment allocated by randomisation (Treatment Phase).

To compare two daily geko™ device treatment durations, six hours and 12 hours, in conjunction with SC, with each other and to SC alone, in patients with venous leg ulcers

Detailed Description

1. Screen patient database to identify eligible patients 2. Obtain informed consent and inform participant's GP 3. Complete CRF throughout the study period (demographics, vital signs, medical history, study ulcer history, concomitant medication) 4. Physical examination at the study start up visit and at consecutive weekly visits 5. Take a digital image of the wound at participants weekly visits 6. Assess and report adverse events 7. Apply standard care (compression bandaging) at weekly visits and record all the dressing usage 8. Perform randomisation at the end of week 4 and allocate participant to one of the three treatment groups. 9. Train the participant to use gekoTM devices 10. Schedule weekly visits

Registry

clinicaltrials.gov

Start Date

April 24, 2018

End Date

August 9, 2022

Last Updated

2 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Firstkind Ltd

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Potential subjects are required to meet all of the following criteria for enrollment into the study and subsequent randomization.
•Male or female aged ≥ 18 years and able to provide written informed consent.
•Intact healthy skin at the site of gekoTM device application.
•Patients who have a chronic venous leg ulcer determined to be due to underlying venous disease following evaluation in a multidisciplinary clinic setting.
•A VLU of approximately ≥ 3cm2 and ≤ 39 cm2 at study enrolment i.e. Run In Phase Visit 1 (RV1). The largest ulcer within the given size range will be designated the study ulcer and the only one included in the study. If other ulcerations are present on the same leg they have to be more than 2 cm apart if they are separate wounds.
•Study ulcer (current episode of ulceration in case of ulcer recurrence) has been present for at least 6 weeks but no more than 5 years prior to study entry (i.e. RV1).
•Ankle-Brachial Pressure Index (ABPI) of 0.75-1.24 inclusive measured at study entry or within 8 weeks prior to study entry (i.e. RV1).
•No active local or systemic infection for a minimum of 48 hours prior to study entry (i.e. RV1).
•No systemic antimicrobial treatment for a minimum of seven days prior to study entry prescribed for index wound infection (i.e. RV1).
•Patient understands and is willing to participate in the study and is able to comply with study procedures and visits.

Exclusion Criteria

•Potential subjects meeting any of the following criteria will be excluded from enrollment and subsequent randomisation:
•Known allergy to any of the protocol-stipulated treatments, or non-tolerance of multilayer, multicomponent compression therapy.
•History of significant haematological disorders (e.g. Sickle Cell disease).
•History of Deep Vein Thrombosis (DVT) within six months preceding study entry (i.e. RV1).
•History of Pyoderma Gangrenosum or other inflammatory ulceration.
•Pregnancy or breast feeding.
•Use of investigational drug or device within four weeks prior to study entry (i.e. RV1) that may interfere with this study.
•Use of any neuro-modulation device.
•Surgery during three months prior to study entry (such as abdominal, gynaecological, hip or knee replacement) (i.e. RV1).
•Trauma to the lower limbs that would prevent geko™ from stimulating the common peroneal nerve.